Epigenomic annotation of noncoding mutations identifies mutated pathways in primary liver cancer.
Evidence that noncoding mutation can result in cancer driver events is mounting. However, it is more difficult to assign molecular biological consequences to noncoding mutations than to coding mutations, and a typical cancer genome contains many more noncoding mutations than protein-coding mutations...
Main Authors: | Rebecca F Lowdon, Ting Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5363827?pdf=render |
Similar Items
-
The role of noncoding mutations in blood cancers
by: Sunniyat Rahman, et al.
Published: (2019-11-01) -
Pan-cancer noncoding genomic analysis identifies functional CDC20 promoter mutation hotspots
by: Zaoke He, et al.
Published: (2021-04-01) -
Cancer Risks Linked to the Bad Luck Hypothesis and Epigenomic Mutational Signatures
by: José E. Belizário
Published: (2018-07-01) -
Population Genetic Annotation of the Human Genome: Identifying Pathogenic Mutations
by: Gussow, Ayal Baruch
Published: (2016) -
The influence of epigenomic and transcriptomic features in normal tissues on the mutational landscape across cancers
by: Tiong Khong Loon, et al.
Published: (2017)